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Abstract
Background Converging evidence indicates that prenatal
exposure to immune challenge can induce long-term
cognitive deficits relevant to schizophrenia. Such cognitive
impairments may be related to deficient hippocampal
neurogenesis at adult age.
Objectives In the present study, we sought evidence for the
possibility that chronic treatment with the reference atypical
antipsychotic drug clozapine may improve prenatal
infection-induced cognitive dysfunctions by stimulating
adult hippocampal neurogenesis.
Methods This hypothesis was tested in a well-established
mouse model of prenatal immune challenge which is based on
prenatal administration of the viral mimic, polyriboinosinic–
polyribocytidilic acid (PolyI:C).
Results We found that maternal PolyI:C (5 mg/kg, i.v.)
exposure on gestation day 17 led to significant spatial
working memory impairment and reduced hippocampal
neurogenesis in the resulting offspring at adult age. The
latter effect was apparent in postmortem immunohisto-
chemical analyses of the cell proliferation marker bromo-
deoxyuridine and the microtubule-associated protein
doublecortin, a marker of newborn neuronal cells. Chronic
(3 weeks) administration of clozapine (5 mg/kg/day, i.p.)
significantly improved the prenatal PolyI:C-induced work-
ing memory deficits, while at the same time, it negatively
affected working memory performance in adult offspring
born to control mothers. These bidirectional cognitive
effects of clozapine were not paralleled by concomitant
effects on adult hippocampal neurogenesis.
Conclusions Our findings do not support the hypothesis
that the atypical antipsychotic drug clozapine may influence
cognitive functions by acting on adult neurogenesis in the
hippocampus, regardless of whether the drug is adminis-
tered to subjects with or without a neurodevelopmental
predisposition to adult neuropathology.
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Introduction
Maternal infection during pregnancy is a known environ-
mental risk factor for the development of schizophrenia and
related disorders (Brown and Susser 2002; Fatemi 2005;
Brown 2006; Patterson 2007). Even though the precise
neuroimmunological mechanisms involved still need to be
delineated, one prevalent hypothesis suggests that infection-
induced disruption of fetal neurodevelopmental processes
may predispose the organisms to long-lasting changes in
subsequent brain and behavioral development, thereby
increasing the risk of psychotic disturbances in later life
(Gilmore and Jarskog 1997; Patterson 2002; Fatemi 2005;
Meyer et al. 2007, 2009b). This hypothesis has been
substantiated by numerous investigations in experimental
rodent models demonstrating the emergence of altered fetal
brain development (Meyer et al. 2008a) and multiple long-
term brain and behavioral abnormalities relevant to schizo-
phrenia following prenatal exposure to infection and/or
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immune activation (for recent reviews, see Meyer et al.
2009a; Meyer and Feldon 2009; Patterson 2009).
One of the critical psychopathological outcomes of
prenatal immune challenge is the appearance of cogni-
tive impairments. Experimental data show that prenatal
exposure to immune-activating agents such as the
bacterial endotoxin lipopolysaccharide (LPS), the viral
mimic polyriboinosinic–polyribocytidilic acid (PolyI:C),
or the pro-inflammatory cytokine interleukin-6 induces
long-term cognitive impairments in the form of defi-
ciencies in spatial working memory (Meyer et al. 2005,
2008b) and reference memory (Samuelsson et al. 2006),
novel object recognition (Ozawa et al. 2006; Coyle et al.
2009), and discrimination reversal learning (Zuckerman
and Weiner 2005; Meyer et al. 2006). These experimental
findings are complemented by the recent pioneering
findings by Brown and colleagues showing that prenatal
exposure to viral infection is associated with executive
dysfunctions in patients with schizophrenia (Brown et al.
2009). Hence, there is converging evidence derived from
both experimental and epidemiological studies supporting
a causal relationship between prenatal immune challenge
and emergence of cognitive impairments relevant to
schizophrenia.
It has recently been demonstrated that impaired adult
neurogenesis in the hippocampus (HPC) is involved in the
cellular neuropathology of schizophrenia (Reif et al. 2006).
Adult neurogenesis refers to the generation of new neurons
in the adult brain. This complex multistep process includes
phases of proliferation of progenitor cells, followed by
differentiation and maturation into a neuronal (or glial)
phenotype (for a recent review, see Balu and Lucki 2009).
The HPC is one of the major neurogenic brain regions in
which neurogenesis can occur throughout life (Altman and
Das 1965; van Praag et al. 2002; Kempermann et al. 2004).
This brain structure is also known to be critically involved
in fundamental cognitive functions, especially in spatial
memory (Olton and Papas 1979; Moser et al. 1993; Lee and
Kesner 2003; Bannerman et al. 2004). Furthermore,
structural and functional abnormalities in the HPC are
believed to critically mediate at least some of the cognitive
abnormalities in patients with schizophrenia (Harrison
1999, 2004; Weinberger 1999; Antonova et al. 2004;
Tamminga 2006). Based on the recent findings by Reif
and colleagues (2006), it has been proposed that impaired
adult neurogenesis in the HPC may provide an important
(but relatively unexplored) cellular link between hippocam-
pal abnormalities and emergence of cognitive dysfunctions
in patients with schizophrenia (Reif et al. 2007; Toro and
Deakin 2007; Kempermann et al. 2008). Furthermore, it has
been hypothesized that the beneficial effects of atypical
antipsychotic drugs on cognitive abnormalities in schizo-
phrenic individuals may be accounted for, at least in part,
by an amelioration of deficient hippocampal neurogenesis
(Reif et al. 2006, 2007; Toro and Deakin 2007).
In keeping with the role of prenatal infection in the
etiology of schizophrenia in general and with its impact on
adult cognitive functions in particular, prenatal immune
challenge may induce cognitive disturbances by disrupting
postnatal neurogenesis. Initial support for this hypothesis
has been obtained by recent experimental studies in mice
and rats demonstrating that offspring born to gestationally
immune-challenged mothers display reduced postnatal
hippocampal neurogenesis (Meyer et al. 2006; Cardon et
al. 2009; Cui et al. 2009) together with marked deficits in
various cognitive tasks (reviewed in Meyer et al. 2009a, b;
Meyer and Feldon 2009). However, despite evidence for
beneficial effects of atypical antipsychotic drugs on
cognitive impairments induced by prenatal immune chal-
lenge (Ozawa et al. 2006), it remains essentially unknown
whether these procognitive effects may be related to
possible effects of atypical antipsychotic drugs on adult
hippocampal neurogenesis.
Therefore, the present study was designed to test the
hypothesis that chronic treatment with the reference
atypical antipsychotic drug clozapine (CLZ) may improve
prenatal infection-induced cognitive dysfunctions by stim-
ulating adult hippocampal neurogenesis. For this purpose,
we used a well-established experimental mouse model of
prenatal exposure to a viral-like acute phase response,
which is based on maternal administration of the synthetic
analog of double-stranded RNA, PolyI:C (Meyer et al.
2009a). The effects of prenatal immune challenge on adult
cognitive functions were assessed using a spatial working
memory paradigm known to be sensitive to detect the long-
term cognitive effects of prenatal PolyI:C exposure in mice
(Meyer et al. 2005, 2008b). Adult hippocampal neuro-
genesis was first evaluated by immunohistochemical anal-
yses of bromodeoxyuridine (BrdU) in order to label
mitotically active cells (Dolbeare 1995). In addition, we
performed immunohistochemical investigations of double-
cortin (DCX), a microtubule-associated protein expressed
specifically in newborn neuronal but not glial cells (Francis
et al. 1999; Brown et al. 2003; Couillard-Despres et al.
2005). The latter investigations were conducted in order to
confirm the neuronal phenotype of newly born cells in the
adult HPC.
Materials and methods
Animals
C57BL6/J mice were used throughout the study. Female
and male breeders were obtained from our in-house specific
pathogen-free colony at the age of 10–14 weeks. Breeding
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began after 2 weeks of acclimatization to the new animal
holding room, which was a temperature- and humidity-
controlled (21±1°C, 55±5%) holding facility under a
reversed light–dark cycle (lights off 0800–2000 hours).
All animals had ad libitum access to standard food (Kliba
3430, Klibamühlen, Kaiseraugst, Switzerland) and water.
All procedures described in the present study had been
previously approved by the Cantonal Veterinary Office in
Zurich and were in agreement with the Principles of
Laboratory Animal Care (NIH publication no. 86-23,
revised 1985). All efforts were made to minimize distress
and number of animals used.
Prenatal immune activation
For the purpose of the prenatal immunological manipula-
tion, female mice were subjected to a timed mating
procedure as described previously (Meyer et al. 2005).
Pregnant dams on gestation day (GD) 17 received either a
single injection of PolyI:C (potassium salt; Sigma-Aldrich,
Buchs, St. Gallen, Switzerland) or control (CON; saline)
treatment. A total of ten pregnant mice were included, half
of which were subjected to PolyI:C treatment and the other
half to saline treatment. PolyI:C (5 mg/kg) was dissolved in
sterile and pyrogen-free isotonic 0.9% NaCl (saline)
solution to yield a final concentration of 1 mg/ml. All
solutions were administered via the intravenous (i.v.) route
at the tail vein under mild physical constraint with an
injection volume of 5 ml/kg. All animals were returned to
their home cages immediately after the injection procedure
and left undisturbed until weaning of the offspring.
The dose of PolyI:C (i.e., 5 mg/kg) was selected based
on our previous studies (e.g., Meyer et al. 2005, 2006,
2008b). The chosen gestational window (i.e., GD 17)
corresponds roughly to the middle-to-late second trimester
of human pregnancy in terms of developmental biology and
percentage of gestation (Clancy et al. 2001, 2007). The
selection of this gestational stage was based on our
previous investigations in mice, which demonstrate that
prenatal immune challenge especially in late gestation leads
to marked spatial working memory deficits at adult age
(Meyer et al. 2008b).
Chronic CLZ treatment and BrdU injections
Offspring born to PolyI:C- or control-treated mothers
were weaned and sexed at postnatal day (PND) 21.
Littermates of each sex were caged separately and kept
in groups of four to six animals per cage. All animals
were maintained under ad libitum food and water diet
and kept in a temperature- and humidity-controlled
animal vivarium under a 12:12-h reversed light–dark
cycle as described above.
The chronic drug regime started when the offspring
reached 12 weeks of age and lasted for 3 weeks (see
schematic representation of the study design in Fig. 1a).
During this period, the animals were given daily injections
of CLZ (5 mg/kg) or vehicle (VEH) via the intraperitoneal
(i.p.) route. The dose of CLZ was based on previous studies
showing that chronic (3 weeks) CLZ exposure at a dose of
5 mg/kg (i.p.) is efficient in improving prenatal PolyI:C-
induced cognitive dysfunctions in adult mice (see Ozawa et
al. 2006). CLZ powder (Novartis, Basel, Switzerland) was
first dissolved in 0.1 N hydrochloric acid (HCl) in 0.9%
isotonic NaCl solution and then neutralized with Na2CO3 to
yield a final pH of ∼5.5. VEH-treated animals received
NaCl solution with the appropriate amounts of 0.1 N HCl
and Na2CO3 (pH∼5.5).
One day following cessation of the chronic CLZ or VEH
treatment, all animals were assigned to a BrdU injection
regime following a modified protocol described by Kralic
et al. (2005). BrdU (Sigma, Switzerland) was dissolved in
0.9% NaCl and administered i.p. twice daily (0900 and
1900 hours) on three subsequent days at a concentration of
50 mg/kg in a 10-mg/ml volume (see Fig. 1a).
Each experimental group consisted of one to two
offspring derived from multiple independent litters (five
PolyI:C litters and five control litters). Only male subjects
were included in the working memory test and subsequent
postmortem immunohistochemical investigations. The
number of subjects in each of the four experimental groups
(i.e., CLZ-treated PolyI:C offspring, VEH-treated PolyI:C
offspring, CLZ-treated CON offspring, and VEH-treated
CON offspring) was N=8 male offspring.
Cognitive phenotyping
Cognitive testing of CLZ- or VEH-treated PolyI:C and
control offspring was performed using a spatial working
memory task in the Morris water maze. The test of
spatial working memory in the Morris water maze
commenced 1 day after the third BrdU injection day
(see Fig. 1a). The apparatus consisted of a white
fiberglass tank (1 m diameter) as fully described before
(Meyer et al. 2005). It was positioned in the middle of a
well-lit room enriched with distal spatial cues and
contained a clear Plexiglas cylinder (7 cm in diameter) to
provide an escape platform.
After a 1-day pretraining session with the platform
visible in the center of the maze, the animals were tested in
a working memory task lasting for eight consecutive days.
The working memory test was based on the matching-to-
position paradigm, in which the animals were required to
learn the novel position of a hidden platform located on
trial one of each day in order to navigate effectively to the
same location (i.e., matching) on the subsequent trial on the
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same day (Steele and Morris 1999). Hence, each test day
included two trials. The hidden platform remained in the
same position across trials on a given test day but took a
new position on each test day. The daily change of the
platform position ensured that the information acquired on
a given day was irrelevant for the next day, thus taxing the
flexible use of working memory (Baddeley 2003). To begin
each trial, an animal was placed gently in the water maze
against the maze wall at one of the four cardinal positions
(N, E, S, W) and was allowed a maximum of 60 s to locate
the platform. If it failed to reach the platform, it was then
guided to it by the experimenter. Each animal was allowed
to spend 10 s on the platform before commencement of the
next trial.
To manipulate the retention demand in the temporal
domain, the intertrial interval varied between trials 1 and 2.
First, a “minimal delay” of 10–15 s was used for four
consecutive days (days 1–4). This minimal delay referred to
the time the animals spent on the platform in trial 1 of the
test. In the “delay condition” (days 5–8), the animals were
presented with an additional intertrial delay of 60 s, during
which they were kept in a waiting box filled with sawdust.
Escape latency and distance swum were calculated for
each trial. The critical measure of working memory in this
task is the reduction in time spent and/or distance swum to
find the submerged platform in trial 2, compared with trial
1 (when the platform location was essentially unknown to
the subjects). Data collection was achieved using the
Ethovision tracking system (Noldus Information Technolo-
gy, Wageningen, The Netherlands).
Immunohistochemistry
Two days after completion of the working memory test, all
animals were sacrificed to perform the immunohistochem-
ical investigations. The animals were anesthetized with an
overdose of NembutalTM (Abbott Laboratories, North
Chicago, IL, USA) and perfused transcardially with 0.9%
NaCl, followed by 4% phosphate-buffered paraformalde-
hyde solution containing 15% picric acid. The dissected
Fig. 1 a General study design. Pregnant C57BL/6 mice were treated
with PolyI:C (5 mg/kg, i.v.) or corresponding control (saline) solution
on gestation day 17. The resulting offspring were then subjected to
chronic clozapine (CLZ; 5 mg/kg/day, i.p.) or vehicle (VEH) treatment
when they reached the adult stage of development, i.e., for 3 weeks
starting from PND 85–106. One day following cessation of the
chronic drug regime, all offspring were injected with bromodeoxyur-
idine (BrdU; 50 mg/kg) twice daily on three subsequent days (PND
107–109). The offspring were then subjected to cognitive testing in a
spatial working memory task on the next 8 days (PND 100–118). Two
days after completion of cognitive testing (PND 120), all animals were
sacrificed for the purpose of immunohistochemical evaluation of BrdU
and doublecortin (DCX) expression in the dentate gyrus. b Schematic
coronal brain sections delineating the hippocampal areas investigated
with reference to bregma (adapted from The mouse brain in
stereotaxic coordinates by Franklin and Paxinos 2008). Counting of
BrdU and DCX immunoreactivity cells was performed in the dentate
gyrus (DG) region of the complete (i.e., dorsal plus ventral)
hippocampus. All immunohistochemical analyses were performed on
sections ranging from bregma −1.3 to −3.4 mm according to The
mouse brain in stereotaxic coordinates (Franklin and Paxinos 2008).
CA1 field CA1 hippocampus, CA3 field CA3 hippocampus
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brains were postfixed in the same fixative for 6 h and
processed for antigen retrieval involving overnight incuba-
tion in citric acid buffer (pH=4.5) followed by a 90-s
microwave treatment at 480 W (Fritschy et al. 1998). The
brains were then cryoprotected using 30% sucrose in
phosphate buffered saline (PBS) and frozen with powdered
dry ice.
Coronal sections (40 μm thick) were cut from frozen
blocks on a sliding microtome, and eight randomly sampled
series of sections from Bregma −0.8 to −3.6 mm were
collected, rinsed in PBS, and stored at −20°C in antifreeze
solution until further processing. For immunostaining, the
slices were first rinsed three times for 10 min in PBS.
Blocking was done in PBS, 0.3% Triton X-100, and 5%
normal serum for 1 h at room temperature. The following
primary antibodies were used: rat anti-BrdU (Oxford
Biotechnology Ltd., Kidlington, UK; diluted 1:3,000) and
horse anti-DCX (Santa Cruz Biotechnology, Santa Cruz,
CA, USA; diluted 1:1,000). The primary antibodies were
diluted in PBS containing 2% normal goat serum and 0.3%
Triton X-100 and incubated overnight at room temperature.
After three washes with PBS, the sections were incubated
with the biotinylated secondary goat antibody (Jackson
ImmunoResearch Laboratories Inc., West Grove, PA,
USA), diluted 1:500 in antibody buffer for 1 h at room
temperature. The sections were washed again three times
for 10 min in PBS and incubated with Vectastain Kit
(Vector Laboratories; Burlingame, CA, USA) diluted in
PBS for 1 h. After three rinses in Tris–HCl 0.1 M (pH=
7.4), the sections were stained with 1.25% 3,3-diamino-
benzidine and 0.08% H2O2 for 10 min, rinsed four times in
PBS, dehydrated, and cover-slipped with Eukid® (Kindler
GmbH, Freiburg, Germany).
Counting of BrdU- and DCX-positive cells
The total numbers of BrdU- and DCX-positive cells were
estimated in the right dentate gyrus (DG), thereby including
both dorsal and ventral parts. The DG was delineated
according to The mouse brain in stereotaxic coordinates by
Franklin and Paxinos (2008). Counting of BrdU- and DCX-
positive cells was conducted on brain sections ranging from
Bregma −1.3 to −3.4 mm according to The mouse brain in
stereotaxic coordinates (Franklin and Paxinos 2008).
Schematic coronal brain sections of the hippocampal area
of interest with reference to Bregma are provided in
Fig. 1b.
For each animal, every section out of a one-in-eight
series was measured, resulting in an average of six sections
per animal. The majority of newborn (immature) neurons in
the DG resides in a narrow band of tissue, namely the
subgranular zone (SGZ). Since the SGZ is only about two
to three nuclei wide (Kralic et al. 2005; Rahimi and
Claiborne 2007; see also Figs. 3 and 4), BrdU- and DCX-
positive cells were counted exhaustively using live micros-
copy (Zeiss Axioplan microscope, Zeiss, Jena, Germany)
with a 40× objective (numerical aperture, 0.45). Every
labeled cell within the outlined DG of the right brain
hemisphere was counted using a marker tool in Stereo
Investigator (version 6.50.1, Microbrightfield, Colchester,
VT, USA). The total number of BrdU- and DCX-positive
cells in the DG was estimated according to the formula:
CellsTot ¼
P
Cells  1=ssf , where ssf = section sampling
fraction (1/8). For the analysis, total estimated BrdU- and
DCX-positive cells per unit volume (cells per cubic
millimeter) in the SGZ and the granule cell layer (GCL)
of the DG were taken into account for each animal.
Counting of cells was performed blind to the animals’
prenatal treatment and adult drug conditions.
Statistical analysis
All data were analyzed using parametric ANOVA. In the
working memory test, the latency and distance swum to
find the submerged platform were analyzed with the
between-subjects factors of prenatal treatment and adult
drug treatment and with the within-subjects factors of trials
and days. The data collected on the two phases of the
working memory test (i.e., in the “minimal delay condition”
and “60-s delay condition”) were analyzed separately.
Hence, a 2×2×2×4 (prenatal treatment×antipsychotic drug
treatment×trials×days) ANOVA of repeated measures was
used for both delay conditions. Whenever appropriate,
additional 2×4 (trials×days) ANOVAs restricted to each of
the four experimental groups were used to verify the
presence of a significant trial effect in each group.
Estimates of BrdU- and DCX-positive cells in the DG
were analyzed using a 2×2 (prenatal treatment×adult drug
treatment) ANOVA. Statistical significance was set at p<
0.05. All statistical analyses were conducted using the
statistical software StatView (version 5.0) implemented on
a personal computer running the Windows XP operating
system.
Results
Effects of prenatal immune challenge and chronic clozapine
treatment on spatial working memory
Pretraining Animals from all experimental groups were
able to locate the visible platform positioned in the center of
the maze during the 1-day pretraining session. However,
one animal from the VEH-treated PolyI:C group and one
animal from the CLZ-treated PolyI:C group displayed
excessive floating behavior. These two animals were
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therefore excluded from the subsequent working memory
task and immunohistochemical investigations.
Minimal delay condition No group differences were
detected in the latency and distance swum to find the
submerged platform from trial 1 (when the location of the
platform was essentially unknown to the animals) to trial 2
when the animals were tested using a minimal (10–15 s)
intertrial delay (Fig. 2a). For all groups, the latency and
distance swum to find the platform was reduced in trial 2
relative to trial 1 (Fig. 2a), indicating intact spatial working
memory when tested under the minimal delay condition.
ANOVA of escape latency and distance swum only
revealed a highly significant main effect of trials (latency:
F(1, 26)=28.9, p<0.001; distance: F(1, 26)=37.8,
p<0.001). No interactions involving the between-subjects
factors of prenatal treatment and/or adult drug treatment
attained statistical significance.
Sixty-second delay condition Prenatal PolyI:C-induced im-
mune challenge led to impaired working memory perfor-
mance when the interval between trials 1 and 2 on each of
the subsequent four test days was increased to 60 s.
Importantly, the prenatal PolyI:C-induced working memory
deficit was normalized by chronic CLZ treatment. Hence,
while CLZ-treated PolyI:C offspring displayed a clear
reduction in the latency and distance swum from trials 1
to 2 under the 60-s delay condition, VEH-treated PolyI:C
offspring did not (Fig. 2b). Interestingly, chronic CLZ
treatment exerted opposite effects on working memory
performance in offspring born to control mothers: While
VEH-exposed control offspring also showed a significant
reduction in the latency and distance swum from trials 1 to
2, CLZ-treated control offspring were similar to VEH-
treated PolyI:C offspring in failing to show a comparable
improvement (Fig. 2b).
Statistical support for these impressions was yielded by
the significant three-way interaction between prenatal
treatment, adult drug treatment, and trials in the ANOVA
of escape latency (F(1, 26)=4.2, p<0.05) and distance
swum (F(1, 26)=4.4, p<0.05). Subsequent analyses re-
stricted to each experimental group were then conducted in
order to verify the presence of a significant trial effect
during the 4 days of testing under the 60-s delay condition.
These analyses confirmed the significant reduction in time
spent and distance swum to find the platform in trial 2
relative to trial 1 in both VEH-treated control offspring
(main effect of trials for latency: F(1, 21)=8.1, p<0.05;
main effect of trials for distance: F(1, 21)=7.4, p<0.05) and
CLZ-treated PolyI:C offspring (main effect of trials for
latency: F(1, 18)=16.8, p<0.01; main effect of trials for
distance: F(1, 18)=15.1, p<0.01), but not in the other two
groups (F’s<1, n.s.).
Effects of prenatal immune challenge and chronic CLZ
treatment on BrdU-positive cells in the DG
BrdU-positive cells were clearly identifiable in both the
dorsal and ventral hippocampus by the presence of
darkly stained cell bodies (see Fig. 3a). Consistent with
the neurogenic capacity of the DG in the adult HPC (Balu
and Lucki 2009), BrdU-immunoreactive cells were
primarily found in the DG region. Most importantly,
adult offspring born to gestationally immune-challenged
mothers showed a significant reduction in the number of
BrdU-positive cells in the DG compared to adult control
offspring (Fig. 3b). The prenatal infection-induced
decrease in BrdU-immunoreactive cells was noticeable
in both CLZ- and VEH-treated subjects, indicating that
chronic CLZ administration did not exert any influence
on the number of BrdU-positive cells in offspring born
to immune-challenged mothers (Fig. 3b). Similarly,
chronic CLZ treatment did also not significantly affect
the number of BrdU-immunoreactive cells in adult
offspring born to control mothers relative to VEH
treatment in corresponding control offspring (Fig. 3b).
Statistical support for these impression was obtained by
the ANOVA of BrdU-positive cells in the DG, which
revealed only a significant main effect of prenatal
treatment (F(1, 26)=8.93, p<0.01).
Effects of prenatal immune challenge and chronic CLZ
treatment on DCX-positive cells in the DG
DCX-positive cells were also clearly identifiable in the DG
region of the dorsal and ventral hippocampal formation.
Darkly stained DCX-positive cell bodies were found
primarily in the SGZ of the DG and, to a lesser extent, in
the outer zones of the GCL (see Fig. 4a). The DCX-positive
cells in the SGZ and GCL also displayed the characteristic
dendritic trees extending into the inner molecular layer (see
Fig. 4a).
Consistent with the results obtained in the analysis of
BrdU-positive cells (see Fig. 3), adult offspring born to
gestationally immune-challenged mothers showed a marked
decrease in the number of DCX-positive cells in the DG
compared to adult control offspring (Fig. 4b). Again,
chronic CLZ treatment did not exert any significant
influence on the number of DCX-positive cells regardless
of the prenatal immunological treatment (Fig. 4b). The
numbers of DCX-positive cells were thus highly compara-
ble between VEH- and CLZ-treated control offspring and
between VEH- and CLZ-treated PolyI:C offspring (Fig. 4).
Statistical support for this impressions was yielded by the
ANOVA of DCX-positive cells in the DG, which revealed
only a significant main effect of prenatal treatment (F(1,
26)=4.79, p<0.05).
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Discussion
The present study sought evidence for the hypothesis that
chronic treatment with the atypical antipsychotic drug CLZ
may improve prenatal infection-induced cognitive dysfunc-
tions by stimulating adult hippocampal neurogenesis. Using
a well-established mouse model of prenatal immune
challenge by the viral mimic PolyI:C (Meyer et al. 2009a,
b), our results do not support this hypothesis. Consistent
with the earlier reports of beneficial effects of CLZ on
other prenatal infection-induced behavioral and cognitive
abnormalities (Shi et al. 2003; Zuckerman et al. 2003;
Zuckerman and Weiner 2005; Ozawa et al. 2006), we found
that chronic CLZ treatment significantly improved spatial
working memory deficits in adult offspring born to
immune-challenged mothers. However, these procognitive
effects of the drug treatment were not related to concom-
itant effects on adult hippocampal neurogenesis. Hence,
adult offspring born to PolyI:C-exposed mothers displayed
a significant reduction in BrdU- and DCX-immunoreactive
cells regardless of whether they were subjected to chronic
CLZ treatment or not. In accordance with the drug’s null
effect on adult hippocampal neurogenesis in prenatally
immune challenged animals, chronic CLZ treatment did
also not significantly affect the expression of cellular
markers of adult neurogenesis in adult control offspring
(Figs. 3 and 4). However, the chronic drug regime
negatively affected working memory performance in adult
offspring born to control mothers. Taken together, our
findings thus suggest that chronic CLZ treatment can have
Fig. 2 Effects of prenatal immune activation and chronic clozapine
(CLZ) treatment on spatial working memory in a matching-to-position
water maze task. The graph depicts the latency and distance swum to
find the submerged platform in trial 1 (when the location of the
platform was unknown to the animals) and in trial 2. Working memory
was indexed by the reduction in the latency and distance swum from
trial 1 to trial 2. a Neither prenatal immune challenge by the viral
mimic PolyI:C nor chronic treatment with the atypical antipsychotic
drug CLZ significantly affected working memory performance when
the animals were tested in trials presented with a minimal (10–15 s)
interval between trials 1 and 2. Hence, a clear reduction in the latency
and distance swum to find the platform in trial 2 relative to trial 1 was
noticeable in both CLZ- or vehicle (VEH)-treated PolyI:C and control
offspring. #p<0.001 refers to a statistical significance associated with
the main effect of trials taken from the corresponding ANOVA. b
When the interval between trials 1 and 2 was extended to 60 s,
working memory was markedly impaired in VEH-treated PolyI:C
offspring and in CLZ-treated control offspring. Only VEH-treated
control offspring and CLZ-treated PolyI:C offspring displayed a
significant reduction in the latency and distance swum in trial 2
relative to trial 1. VEH-treated PolyI:C offspring and CLZ-treated
control offspring did not show a similar improvement. *p<0.05 and
**p<0.01 refer to a statistical significance associated with the
significant main effect of trials in the ANOVA restricted to each
experimental group. All values are means±SEM
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bidirectional effects on working memory performance
depending on whether the treated subjects were predisposed
to adult neuropathology by prenatal immune challenge or
not and that this causal relationship is independent of adult
hippocampal neurogenesis.
In full agreement with our previous findings (Meyer et
al. 2005, 2008b), the prenatal infection-induced working
memory impairment was only apparent in conditions, in
which the demand in temporal retention was accentuated by
increasing the delay between the two relevant test trials: All
animals showed normal working memory performance
when tested under the minimal delay condition (10–15 s);
however, a significant impairment was evident in prenatally
PolyI:C-exposed offspring when the delay between trials 1
and 2 of the working memory test was extended to 60 s
(Fig. 2). This indicates that the working memory impair-
ment in prenatally immune-challenged subjects may be
accounted for by deficits in mnemonic processing (Olton et
al. 1986; Delatour and Gisquet-Verrier 1999; Broersen
2000). According to this interpretation, working memory is
normal under low working memory demand, but significant
impairment emerges when the mnemonic flexibility re-
quired by the working memory task is accentuated by
additional storage load in the temporal domain. Interest-
ingly, the CLZ-induced disruption of working memory in
offspring born to control mothers was also only evident in
conditions, in which the demand in temporal retention was
accentuated by increasing the delay between the two
relevant test trials (Fig. 2). One possible explanation would
therefore be that the CLZ-induced disruption of working
memory in offspring born to control mothers could be
related to drug-induced changes in mnemonic functions.
The present findings of bidirectional cognitive effects of
chronic CLZ treatment are striking but not unprecedented.
Indeed, previous experimental research in rats has already
provided direct evidence that the outcomes of therapeutic
CLZ treatment on working memory performance can
critically differ between intact control subjects and subjects
with preexisting brain lesions, especially within the
hippocampal formation. For example, CLZ treatment is
efficient in improving working memory deficits in rats with
fimbria-fornix lesions, while at the same time it impairs
working memory in sham-operated control rats (Addy et al.
2005). Likewise, CLZ treatment at doses that lead to
significant working memory impairment in intact animals
significantly improves working memory deficits induced by
chronic blockade of hippocampal α4β2 nicotinic receptors
(Pocivavsek et al. 2006). In addition to the deficits in adult
hippocampal neurogenesis reported here, prenatal immune
activation in rodents is known to result in a wide spectrum
Fig. 3 Bromodeoxyuridine (BrdU) immunoreactivity in the dentate
gyrus of adult offspring born to PolyI:C-exposed or control mothers. a
The photomicrographs show coronal brain sections of representative
adult control and PolyI:C offspring displaying high and low numbers
of BrdU-positive cells (indicated by the arrows), respectively, in the
dentate gyrus at the level of the dorsal hippocampal formation. As
evident in the images at a higher magnification (indicated by the
squares), darkly stained BrdU-positive cell bodies were found
primarily in the subgranular zone (SGZ) and, to a notably lesser
extent, in the granular cell layer (GCL) and molecular layer (ML) of
the dentate gyrus. Scale bars=250 μm. b Adult offspring born to
PolyI:C-treated mothers showed a significant reduction in the number
of BrdU-positive cells in the dentate gyrus compared to adult offspring
born to control mothers. Chronic clozapine (CLZ) treatment did not
significantly influence the number of BrdU-positive cells compared
with corresponding vehicle (VEH) treatment in adult control or PolyI:C
offspring. *p<0.05 refers to a statistical significance associated with the
main effect of prenatal treatment in the corresponding ANOVA. All
values are means±SEM
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of morphological and neurochemical alterations in hippo-
campal structures at adult age (for recent reviews, see
Meyer et al. 2009a, b; Meyer and Feldon 2009). Hence,
presence or absence of hippocampal neuropathology may
provide a neural explanation for the bidirectional effects of
chronic CLZ treatment in prenatally immune challenged
and control offspring.
The existence of HPC-dependent bidirectional effects
of CLZ on cognitive functions may also have important
implications for the effectiveness of this atypical antipsy-
chotic drug in improving cognitive impairment in patients
with schizophrenia. There are some reports that CLZ can
significantly improve working memory dysfunctions in
schizophrenic patients (e.g., Grace et al. 1996; Galletly et
al. 1997, 2005; Sharma et al. 2003), as opposed to several
findings reporting no or even detrimental effects of
chronic CLZ treatment on working memory performance
in affected individuals (e.g., Hagger et al. 1993; Lee et al.
1999; Adler et al. 2002; McGurk et al. 2005). While there
has been a long discussion on the involvement of
hippocampal dysfunctions in the neuropathology and
pathophysiology of schizophrenia (Harrison 1999, 2004;
Weinberger 1999; Antonova et al. 2004; Tamminga
2006), the nature and/or severity of hippocampal abnor-
malities are likely to differ considerably between individ-
ual subjects suffering from this disorder. Varying degrees
of hippocampal dysfunction may thus not only determine
the specificity of symptom clusters in schizophrenia
(O'Donnell and Grace 1998) but also critically influence
the effects of atypical antipsychotic drug treatment on
behavioral and cognitive symptoms, including working
memory.
One of the main findings of the present study is that
prenatal exposure to a viral-like acute phase response leads
to long-term deficits in adult hippocampal neurogenesis.
This extends our previous report of deficient hippocampal
neurogenesis in juvenile offspring born to gestationally
PolyI:C-exposed mice (Meyer et al. 2006). Furthermore,
the neurogenesis-disrupting effects of prenatal viral-like
immune activation reported here are in agreement with the
recent experimental data obtained in a rat model of prenatal
immune challenge induced by the bacterial endotoxin LPS
(Cui et al. 2009). Hence, various types of immune-
associated prenatal insults can induce robust deficits in
Fig. 4 Doublecortin (DCX) immunoreactivity in the dentate gyrus of
adult offspring born to PolyI:C-exposed or control mothers. a The
photomicrographs show coronal brain sections of representative adult
control and PolyI:C offspring displaying high and low numbers of
DCX-positive cells, respectively, in the dentate gyrus at the level of the
dorsal hippocampal formation. As evident in the images at a higher
magnification (indicated by the squares), darkly stained DCX-positive
cell bodies were found primarily in the subgranular zone (SGZ). These
DCX-positive cells extend characteristic dendritic trees through the
granular cell layer (GCL) into the inner molecular layer (ML) of the
dentate gyrus. Scale bars=250 μm. b Adult offspring born to PolyI:C-
treated mothers showed a significant reduction in the number of DCX-
positive cells in the dentate gyrus compared to adult offspring born to
control mothers. Chronic clozapine (CLZ) treatment did not signifi-
cantly influence the number of DCX-positive cells compared with
corresponding vehicle (VEH) treatment in adult control or PolyI:C
offspring. *p<0.05 refers to a statistical significance associated with
the main effect of prenatal treatment in the corresponding ANOVA.
All values are means±SEM
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postnatal hippocampal neurogenesis across juvenile to adult
stages of development.
In the present study, adult hippocampal neurogenesis
was studied by postmortem investigations of BrdU and
DCX immunoreactivity in the DG. Antibodies directed
against the microtubule-associated protein DCX have been
consistently shown to label newly generated postmitotic
neurons before they reach full maturation (Francis et al.
1999; Brown et al. 2003; Couillard-Despres et al. 2005).
DCX is thus a valuable marker to investigate aspects of
neurogenesis which are associated primarily with the
developmental processes occurring between neuronal dif-
ferentiation and maturation. The prenatal PolyI:C-induced
deficit in hippocampal DCX immunoreactivity (Fig. 4) can
thus be interpreted as a form of reduced neuronal
differentiation and/or maturation. In addition, we showed
reduced cell labeling of the mitosis marker BrdU in the DG
of prenatally immune-challenged offspring relative to
control offspring (Fig. 3). Our experimental design required
that the animals were sacrificed 10 days following the last
BrdU injection (see Fig. 1). According to current consensus
(Kempermann et al. 2004; Balu and Lucki 2009), evalua-
tion of BrdU-positive cells following such an incubation
interval would provide information about the integration of
newly born cells into the hippocampal formation. Hence,
our analysis of BrdU-positive cells suggests that the
prenatal infection-induced deficit in neuronal differentiation
and/or maturation (as assessed by DCX immunostaining)
may stem from diminished neuronal cell integration in the
adult DG (Kempermann et al. 2004; Balu and Lucki 2009).
We cannot further conclude from the present results as to
whether these deficits may additionally be related to
reduced cell proliferation in the adult DG of prenatally
immune-challenged animals. This is because we did not
assess BrdU-positive cells using a short-term (2–24 h)
interval between BrdU administration and sacrifice of the
animals. However, recent experimental evidence suggests
that prenatal immune activation is indeed effective in
reducing the capacity of postnatal hippocampal cell prolifer-
ation as assessed by quantification of BrdU-positive cells in
the DG shortly (2 h) after BrdU administration (Cui et al.
2009).
The lack of a significant effect of chronic CLZ treatment
on hippocampal neurogenesis reported here is in agreement
with previous experimental studies showing no significant
effects of acute or chronic treatment with low or high doses
of CLZ on adult hippocampal neurogenesis in rats (Halim
et al. 2004; Schmitt et al. 2004). Since the chosen dose of
CLZ (5 mg/kg/day) proved to be functionally effective in
the assessment of cognitive functions (Fig. 2), it is unlikely
that the null effect of chronic CLZ treatment on adult
hippocampal neurogenesis may be explained by a general
lack of drug effect. Rather, our findings are indicative of a
critical segregation between the effects of chronic CLZ on
cognitive functions and adult hippocampal neurogenesis.
This segregation is strikingly similar to recent experimental
findings in rats suggesting that the therapeutic efficacy of
antidepressant drugs to ameliorate depression-like behav-
ioral abnormalities can be segregated from the drugs’
effects on adult hippocampal neurogenesis (Bessa et al.
2009a, b). However, in contrast to our findings here and the
earlier reports in rats (Halim et al. 2004; Schmitt et al.
2004), a recent study in mice has shown that chronic CLZ
treatment is able to prevent a decrease in adult hippocampal
neurogenesis (as assessed by BrdU labeling in the DG)
induced by repeated administration of the noncompetitive
NMDA-receptor antagonist phencyclidine (PCP; Maeda et
al. 2007). This suggests that even though chronic CLZ
administration may not stimulate adult hippocampal neuro-
genesis per se, it may prevent neurogenesis-disrupting
effects induced by specific (experimental) manipulations.
It is important to emphasize that the PCP-induced impair-
ment in adult hippocampal neurogenesis reported by Maeda
et al. (2007) critically differs from that induced by prenatal
immune challenge: The former is acquired during adult life,
while the latter is present already at juvenile stages of life
(Meyer et al. 2006; Cui et al. 2009). Hence, the efficacy of
CLZ to prevent (experimentally induced) impairments in
adult hippocampal neurogenesis may crucially depend on
the precise developmental window at which the deficit is
induced.
Notably, the significant effects of the prenatal immuno-
logical and adult pharmacological manipulations on spatial
working memory in the water maze clearly dissociated from
their effects on adult hippocampal neurogenesis. Indeed,
while both manipulations exerted a significant (bidirection-
al) influence on working memory (see Fig. 2), only prenatal
PolyI:C-induced immune activation but not chronic CLZ
treatment significantly affected the numbers of BrdU- and
DCX-positive cells in the adult DG (Figs. 3 and 4). This
dissociation may indicate that adult neurogenesis is not
essentially involved in spatial working memory, at least
when assessed in the Morris water maze. This suggestion is
consistent with the findings from numerous attempts to
explore the functional role of the adult DG in general
(Shapiro and Olton 1994; Gilbert et al. 1998, 2001; Kesner
2007; Goodrich-Hunsaker et al. 2008) and of hippocampal
neurogenesis in particular (Clelland et al. 2009). More
specifically, there is experimental evidence to assume
that the contribution of the DG to cognitive functions
may be more directly related to spatial (and temporal)
separation of events associated with transient memory
representations of new spatial information, rather than to
(spatial) working memory representations of new infor-
mation (Gilbert et al. 1998, 2001; Leutgeb et al. 2007).
Of special interest in the present context are the recent
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findings by Clelland et al. (2009) showing that ablation of
hippocampal neurogenesis in adult mice leads to impaired
spatial memory for similar, but not distinct, spatial
locations, emphasizing a crucial role of adult hippocampal
neurogenesis to spatial pattern separation. Given these
novel findings, it would be highly interesting to further
explore the functional role of prenatal infection-induced
impairments in hippocampal neurogenesis in spatial
pattern separation.
In conclusion, the present study demonstrates that
chronic treatment with the reference atypical antipsychotic
drug CLZ significantly influences working memory perfor-
mance without affecting hippocampal neurogenesis in
adulthood. Hence, the beneficial effects of chronic CLZ
on working memory performance in neurodevelopmentally
comprised subjects do not seem to be casually linked to
concomitant effects on adult hippocampal neurogenesis.
With respect to the clinical situation in humans, our
experimental findings thus provide no support for the
recent hypothesis that the beneficial effects of atypical
antipsychotic drugs on working memory dysfunctions in
patients with schizophrenia may be mediated by a rein-
statement of deficient hippocampal neurogenesis (Reif et al.
2006, 2007; Toro and Deakin 2007). Additional inves-
tigations are thus clearly warranted in order to identify the
critical neuropharmacological and cellular mechanisms
underlying the procognitive effects of CLZ treatment, in
general, and in subjects predisposed to adult neuropathol-
ogy by prenatal immune challenge, in particular.
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